Clinical Study

Study Of Amantadine Hcl Extended Release Capsules For The Treatment Of Levodopa Induced Dyskinesia

Posted Date: Apr 15, 2017

  • Investigator: Alberto Espay
  • Co-Investigator: Michele Janszen
  • Specialties: Parkinson's Disease, Neurology, Movement Disorders
  • Type of Study: Drug

Amantadine, in an immediate-release (IR) formulation, is approved by the FDA for the treatment of Parkinson’s disease (PD). Neurologists sometimes also use amantadine to treat levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease, or inv

Criteria:

You Are Being Asked To Participate In This Study Because You Have Parkinson’S Disease And Have Levodopa Induced Dyskinesia. Three Groups Of Lid Patients Are Potentially Eligible To Participate In This Study: • Group 1 Includes Patients Who Are Currently

Keywords:

Adamas Amt-Ads-Pd302, Levodopa Induced Dyskinesia, Amantadine Extended Release, Espay, Parkinson's Disease

For More Information:

Katie Krier
(513) 558-0169
katie.krier@uc.edu

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.